159 related articles for article (PubMed ID: 38140114)
1. Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice through Co-Delivery of Tumor-Associated Mucin-1 Antigen and TLR Agonists in C3-Liposomes.
Arabi A; Aria Soltani S; Maniaci B; Mann K; Martinson H; Kullberg M
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140114
[TBL] [Abstract][Full Text] [Related]
2. Delivery of toll-like receptor agonists by complement C3-targeted liposomes activates immune cells and reduces tumour growth.
Francian A; Widmer A; Olsson T; Ramirez M; Heald D; Rasic K; Adams L; Martinson H; Kullberg M
J Drug Target; 2021 Aug; 29(7):754-760. PubMed ID: 33472457
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice.
Francian A; Namen S; Stanley M; Mann K; Martinson H; Kullberg M
Nanomedicine; 2019 Jun; 18():326-335. PubMed ID: 30419362
[TBL] [Abstract][Full Text] [Related]
4. MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide.
Du JJ; Zhou SH; Cheng ZR; Xu WB; Zhang RY; Wang LS; Guo J
Front Chem; 2022; 10():814880. PubMed ID: 35186882
[TBL] [Abstract][Full Text] [Related]
5. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
[TBL] [Abstract][Full Text] [Related]
6. Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs.
Francian A; Mann K; Kullberg M
Int J Nanomedicine; 2017; 12():5149-5161. PubMed ID: 28790822
[TBL] [Abstract][Full Text] [Related]
7. Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines.
Hossain MK; Wall KA
Vaccines (Basel); 2016 Jul; 4(3):. PubMed ID: 27472370
[TBL] [Abstract][Full Text] [Related]
8. Liposomal co-delivery of toll-like receptors 3 and 7 agonists induce a hot triple-negative breast cancer immune environment.
Nguyen BL; Phung CD; Pham DV; Le ND; Jeong JH; Kim J; Kim JH; Chang JH; Jin SG; Choi HG; Ku SK; Kim JO
J Control Release; 2023 Sep; 361():443-454. PubMed ID: 37558053
[TBL] [Abstract][Full Text] [Related]
9. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
[TBL] [Abstract][Full Text] [Related]
10. Liposomal Antitumor Vaccines Targeting Mucin 1 Elicit a Lipid-Dependent Immunodominant Response.
Du JJ; Zou SY; Chen XZ; Xu WB; Wang CW; Zhang L; Tang YK; Zhou SH; Wang J; Yin XG; Gao XF; Liu Z; Guo J
Chem Asian J; 2019 Jun; 14(12):2116-2121. PubMed ID: 31042017
[TBL] [Abstract][Full Text] [Related]
11. Deletion of the mucin-like molecule muc1 enhances dendritic cell activation in response to toll-like receptor ligands.
Williams MA; Bauer S; Lu W; Guo J; Walter S; Bushnell TP; Lillehoj EP; Georas SN
J Innate Immun; 2010; 2(2):123-43. PubMed ID: 20375631
[TBL] [Abstract][Full Text] [Related]
12. Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays.
Inglefield J; Catania J; Harris A; Hickey T; Ma Z; Minang J; Baranji K; Spangler T; Look J; Ruiz C; Lu H; Alleva D; Reece JJ; Lacy MJ
Vaccine; 2022 Sep; 40(38):5544-5555. PubMed ID: 35773119
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.
Brooks N; Hsu J; Esparon S; Pouniotis D; Pietersz GA
Molecules; 2018 Sep; 23(9):. PubMed ID: 30200528
[TBL] [Abstract][Full Text] [Related]
14. Cytosolic Delivery of Liposomal Vaccines by Means of the Concomitant Photosensitization of Phagosomes.
Hjálmsdóttir Á; Bühler C; Vonwil V; Roveri M; Håkerud M; Wäckerle-Men Y; Gander B; Johansen P
Mol Pharm; 2016 Feb; 13(2):320-9. PubMed ID: 26704885
[TBL] [Abstract][Full Text] [Related]
15. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
[TBL] [Abstract][Full Text] [Related]
16. Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus.
Pecher G; Spahn G; Schirrmann T; Kulbe H; Ziegner M; Schenk JA; Sandig V
Anticancer Res; 2001; 21(4A):2591-6. PubMed ID: 11724326
[TBL] [Abstract][Full Text] [Related]
17. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine.
Samuel J; Budzynski WA; Reddish MA; Ding L; Zimmermann GL; Krantz MJ; Koganty RR; Longenecker BM
Int J Cancer; 1998 Jan; 75(2):295-302. PubMed ID: 9462722
[TBL] [Abstract][Full Text] [Related]
19. Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists.
Stavnsbjerg C; Christensen E; Münter R; Henriksen JR; Fach M; Parhamifar L; Christensen C; Kjaer A; Hansen AE; Andresen TL
J Control Release; 2022 Feb; 342():337-344. PubMed ID: 34973307
[TBL] [Abstract][Full Text] [Related]
20. Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.
Corogeanu D; Zaki K; Beavil AJ; Arnold JN; Diebold SS
PLoS One; 2023; 18(3):e0282831. PubMed ID: 36913398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
